RxDoctor Payments Data

Teresa Shenouda, MD

Ophthalmology · Virginia Beach, VANPI 1134104045

Payments from drug & device makers

$1,076in general payments, 2019–2025

Across 30 payments — averaging $35.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$348
  • Alcon$233
  • AbbVie$174
  • Sun Pharmaceutical Industries Inc.$150
  • Mallinckrodt Hospital Products Inc.$97
  • Dompe US, Inc.$40
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$1,04797%
  • Education$293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,076 in reported general payments places this provider in the 50th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$281,153
Medicare patients
423
Services billed
3,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine27$29,045
LumiganBimatoprost15$5,159
SimbrinzaBrinzolamide/Brimonidine Tart24$5,098
Cyclosporine11$3,658
Prednisolone Acetate55$2,097
Ketorolac Tromethamine54$1,589
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha112$1,241
Bimatoprost11$801
Latanoprost101$687
Timolol Maleate53$564
Doxycycline Hyclate17$360
Prednisone20$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$174$34,20442 claims
AlconSimbrinza$233$5,09824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →